Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells

Abstract

Cancer is the second leading cause of death worldwide. Despite great efforts over many years, today cancer treatment is not very effective. The main reasons for cancer chemotherapy failure are high cytotoxicity, low response rates in solid tumors, and development of resistance. Different experimental studies have shown that drug combination using low toxicity natural compounds such as polyphenols can reduce the required dose of cytotoxic drugs for cancer treatment. The polyphenolic compound, Silymarin (SLM), is an active extract from the seeds of the plant milk thistle (Silybum Marianum). It is well known for its hepatoprotective, antioxidant and chemoprotective effects. In present study, we investigated cytotoxic effects of combined liposomal doxorubicin (DXL) and SLM on 4T1 breast cancer cells at different molar ratios of the two drugs and we focused on elucidating whether the combination of the two drugs could dictate antitumor activity in vitro. Results indicated that SLM-DXL combination at 100 and 300 molar ratios, exert synergistic growth-inhibitory effects. These synergistic effects were observed only at lower SLM-DXL concentrations. In conclusion, it is conceivable that in SLM-DXL combination chemotherapy, drug ratios play a key role which determine the final response following treatment. Thus, using liposomes as targeted drug delivery systems, it would be possible to achieve appropriate combination of the two drugs at correct doses and correct administration intervals clinically. Keywords: Silymarin; Doxorubicin; Liposomes; Combination therapy; 4T1

Keywords

• cancer
• combination therapy
• doxorubicin
• liposome
• silymarin